

**21st Annual John Goldman Conference on
Chronic Myeloid Leukemia: Biology and Therapy
Bordeaux, France
September 12-15, 2019**

These abstracts are presented in alphabetical order according to the name of the first author.

BIOLOGY POSTERS

- POSTER 1: Reporting BCR-ABL:ABL Ratio on the International Scale in CML: A Direct Comparison between Our in House EAC Modified Protocol and the Asuragen Quantidex qPCR BCR-ABL Kit
Rukhsaar Ali, Elizabeth Wilkinson, Paul Evans, James Stevens, Efterpi Papouli
- POSTER 2: CIP2A Alters the Balance of PP2A B Subunits and the Diagnostic Level Can Identify Dasatinib Patients at Risk of Disease Progression.
James Austin, Gemma M Austin, Alison K Holcroft, Laura Scott, Sandra Loaiza, Jane F Apperley, Christopher Law, Laura J Bonnett, Richard E Clark and Claire M Lucas
- POSTER 3: Loss of Interferon Regulatory Factor 8 (IRF8) Is Tumor Suppressive By Engaging the p53 Checkpoint in Hematopoietic Stem Cells
Andreas Burchert, Sabrina Inselmann, Supat Thongjuea, Andreas Neubauer, Adam Mead, Ying Wang
- POSTER 4: C421A ABCG2 Polymorphism and CML Occurrence
Sara Di Giusto, Eleonora Toffoletti, Rossella Stella, Davide Griguolo, Miriam Isola, Giuseppe Damante, Renato Fanin, Daniela Damiani, Mario Tiribelli
- POSTER 5: Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinases Exerts Synergistic Effect Against Chronic Myeloid Leukemia (CML) Cells.
Sylwia Flis, Tomasz Chojnacki, Ewelina Bratek, Tomasz Skorski
- POSTER 6: Genetic and Pharmacological Inhibition of Nox2 Delays the Expansion of Murine BCR-ABL1+ Leukemia
Hanna Grauers Wiktorin, Malin Nilsson, Tina Nilsson, Johan Gustafsson, Ebru Aydin, Anders Ståhlberg, Fredrik Bergh Thorén, Kristoffer Hellstrand, Lars Palmqvist, Anna Martner
- POSTER 7: The Clinical Findings and Biology of CD25 As a Stem Cell Marker of CML
Hidenori Kasahara, Daiki Karigane, Shinichiro Okamoto, Keiyo Takubo
- POSTER 8: Mathematic Modelling of the Impact on the Immune System on Chronic Myelogenous Leukemia Treatment and Its Cessation.
Thomas Lepoutre, Doron Levy, Franck-Emmanuel Nicolini

- POSTER 9: Development of Reference Control Material for the Evaluation of the Cepheid Prototype Xpert® BCR-ABL P190 ASSAY
Yuanyuan Liu, Tran Tran, Phat Nguyen, Huilin Wei, Gwo-Jen Day, Lin Yuan
- POSTER 10: Asciminib Efficacy, ALONE or in Combination with Imatinib or Nilotinib, on Committed and Primitive BCR-ABL1-Positive CML Progenitors
Michele Massimino, Elena Tirro', Chiara Romano, Stefania Stella, Livia Manzella, Francesco Di Raimondo, Fabio Stagno, Paolo Vigneri
- POSTER 11: Leukemic Stem Cells (LSC) in AML and CML Exhibit a Unique Phenotype Including Aberrant Expression of Surface Markers and Target-Antigens
Irina Sadovnik, Harald Herrmann, Katharina Blatt, Gregor Eisenwort, Thomas Rülcke, Susanne Herndlhofer, Michael Willmann, Gabriele Stefanzl, Sigrid Baumgartner, Georg Greiner, Axel Schulenburg, Werner Rabitsch, Martin Bilban, Gregor Hoermann, Berthold Streubel, Wolfgang R. Sperr, Peter Valent
- POSTER 12: Determine White Blood Cell Count (WBCC) Limits and ABL Ct Cut-Off with ABL Copy Number (CN) Calibration for the Xpert® BCR-ABL Ultra Assay
Huilin Wei, Krupa Shridhar, Gwo-Jen Day
- POSTER 13: New Dicarboximides Show Potential As Novel Therapeutics Against CML
Urszula Wojda, Iga Stukan, Marek Gryzik, Mikolaj Zdioruk, Mariola Napiorkowska, Marcin Cieślak, Barbara Nawrot